John P. Sharp was named Chief Financial Officer of Cadrenal Therapeutics, Inc. As of November 8, 2026, Cadrenal Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 3, 2026 to July 10, 2026, naming 2 appointments and 2 departures (Form 8-K, June 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cadrenal Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-10
- · In / out: In · Person: John P. Sharp · Role: Chief Financial Officer · 8-K, 2026-06-29
- · In / out: In · Person: Quang X. Pham · Role: Chief Financial Officer · 8-K, 2026-06-03
Cadrenal Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-03 to 2026-07-10. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Cadrenal Therapeutics, Inc. files it.
Also on the record for Cadrenal Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by The PNC Financial Services Group, Inc. | 8.13% of the class | 5%+ stakes | Source |
| July 15, 2026 | Form D, private offering | $8.84M sold | Form D page | Source |
| April 6, 2026 | Form D, private offering | $7.92M sold | Form D page | Source |
| December 31, 2025 | Form D, private offering | $4.40M sold | Form D page | Source |
| November 14, 2024 | Form D, private offering | $9.43M sold | Form D page | Source |
Selling to them or working with them? See who runs Cadrenal Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cadrenal Therapeutics, Inc. and the records around it.
Cadrenal Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- The PNC Financial Services Group, Inc. also filed stake reports on 9 other companies: Avantis US Large Cap Value ETF (Nov 2026), Invesco China Technology ETF (Nov 2026), Global X Artificial Intelligence & Technology ETF (Aug 2026)
Watch Cadrenal Therapeutics, Inc.
Get an email when Cadrenal Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cadrenal Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cadrenal Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cadrenal Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-10 | Reported | not named in the filing | 8-K, 2026-07-10 | ||
| 2026-06-29 | In | Chief Financial Officer | 8-K, 2026-06-29 | ||
| 2026-06-29 | Out | Director | 2026-06-30 | 8-K, 2026-06-29 | |
| 2026-06-29 | Out | Director | 8-K, 2026-06-29 | ||
| 2026-06-03 | In | Chief Financial Officer | 8-K, 2026-06-03 |
Who leads Cadrenal Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Steven Zelenkofske, departure reported, effective 2026-06-30 (filed 2026-06-29). No successor is named in these filings.
- Chief Financial Officer: John P. Sharp, appointed (filed 2026-06-29).
New leaders reset buying decisions — get the Full Report on Cadrenal Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Cadrenal Therapeutics, Inc. (free up to 3)
Find people with the same kind of experience as the Chief Financial Officer at Cadrenal Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Cadrenal Therapeutics, Inc.Every change, in the filing's words
Reported
On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the "Company"), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the "Separation Date").
- The Company is in the process of conducting a search for Dr. Ferguson's replacement.
- The Company and Dr. Ferguson are negotiating the terms of separation and intend to enter into a separation agreement and release at a future date.
Appointed: John P. Sharp, Chief Financial Officer
On June 25, 2026, the Board of Directors (the "Board") of Cadrenal Therapeutics, Inc. (the "Company") appointed John P. Sharp as Interim Chief Financial Officer of the Company.
Departing: Steven Zelenkofske, Director, effective 2026-06-30
On June 28, 2026, Steven Zelenkofske, a Class III member of the Board, notified the Company of his resignation from the Board, effective June 30, 2026.
Departing: Glynn Wilson, Director
Accordingly, on June 29, 2026, Dr. Glynn Wilson resigned as a Class I director.
- In connection with the appointment, Quang X. Pham ceased to serve as the Company's Interim Chief Financial Officer.
- The Company is conducting a search for a permanent Chief Financial Officer.
- Mr. Sharp, age 61, is a seasoned finance executive with more than 30 years of experience in financial and business planning and currently serves as a Senior Director at Lohman & Associates.
- He has served as Chief Financial Officer for several biopharmaceutical companies since April 2007.
- He has been Chief Financial Officer of Skye Bioscience, Inc. since March 31, 2026.
- From December 2022 to October 2025, he served as Chief Financial Officer of SaNOtize Research and Development Corp. Prior to this, he served as Chief Financial Officer of PhaseBio Pharmaceuticals, Inc. from April 2016 to November 11, 2022; of HUYA Bioscience International, LLC, from March 2014 to December 2015; and of Nasdaq-listed Ligand Pharmaceuticals from April 2007 to March 2014.
- He is also a former auditor with PricewaterhouseCoopers LLP.
- Mr. Sharp received a BS in business administration with an emphasis in accounting from San Diego State University and is a certified public accountant (inactive) in California.
Appointed: Quang X. Pham, Chief Financial Officer
Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
- On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.
- The Company is in the process of conducting a search for Mr. Szot's replacement.
- On June 3, 2026, the Company entered into a separation and release agreement (the "Severance Agreement") with Mr. Szot.
- Within seven days of Mr. Szot's execution of the Severance Agreement, he may revoke the terms thereof.
- Therefore, the Severance Agreement shall not be effective or enforceable until the seven-day revocation period (the "Revocation Period") has expired.
- The Severance Agreement contains a general release of all claims against the Company and its current and former officers, directors, employees, and agents, and a non-disparagement clause relating to the Company or any released party.
- Quang X. Pham, age 61, has served as the Company's Chief Executive Officer since he formed the Company.
- He previously served as Chief Executive Officer, Chairman of the Board of Directors, and co-founder of Espero BioPharma, Inc. ("Espero"), the previous sponsor of the tecarfarin IND, since its formation in March 2015 until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking an assignment of Espero's assets.
Cadrenal Therapeutics, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Cadrenal Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.